Immunogenicity and safety of Havisure < sup > TM < /sup > vaccine developed by Human Biologicals Institute in healthy subjects of 12  months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study

CONCLUSION: The study results indicate that the Havisure™ vaccine is immunogenic and safe when administered to healthy subjects of 12 months to 49 years of age, and is non-inferior to Havrix® Vaccine.PMID:37661535 | DOI:10.1016/j.vaccine.2023.08.084

Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Madhu Gupta Kheya Ghosh Uttam Sonali Palkar Ashish Ramachandra Dhongade K Siva Ram Prasad Vasudev Rajapantula M D Ravi N Pradeep M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research